Ticagre%2525252525252525252525252525252525252525252525252525252520%2525252525252525252525252525252525252525252525252525252528ticagrelor%2525252525252525252525252525252525252525252525252525252529

# Ticagrelor ## Overview Ticagrelor is an oral, direct-acting, reversibly binding P2Y12 receptor antagonist used to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ## Primary Indications * Reduction of thrombotic cardiovascular events in patients with ACS (either with STEMI, NSTEMI, or UA). * In combination with aspirin, for prevention of stent thrombosis in patients treated with a coronary stent. ## Adult Dosing * **ACS:** 180 mg loading dose, followed by 90 mg twice daily. * **Maintenance after ACS (if not at high risk for bleeding):** May continue at 90 mg twice daily. * **Maintenance after ACS (if at high risk for bleeding, or if patient is >12 months post-ACS):** May consider reducing to 60 mg twice daily. * **Stent Thrombosis Prevention:** 90 mg twice daily. **Note:** Duration of therapy depends on the specific ACS presentation, revascularization strategy, and bleeding risk, often guided by local protocols. Standard duration is typically 12 months. ## Pediatric Dosing Ticagrelor is not approved for use in pediatric patients. Safety and efficacy have not been established. ## Dose Adjustments * **Hepatic Impairment:** No dose adjustment needed in mild to moderate hepatic impairment. Use with caution in severe hepatic impairment. * **Renal Impairment:** No dose adjustment needed in mild to moderate renal impairment. Use with caution in severe renal impairment. * **Concomitant Medications:** Avoid concomitant use with strong CYP3A4 inhibitors. Consider dose reduction to 60 mg twice daily if used with strong CYP3A4 inducers or potent P-glycoprotein inhibitors. ## Contraindications * Documented hypersensitivity to ticagrelor or any of its excipients. * Active pathological bleeding. ## Adverse Effects * **Most Common:** Bleeding (dyspnea, bruising, epistaxis, gastrointestinal bleeding, hematuria), bradyarrhythmia. * **Serious:** Severe bleeding events (intracranial, life-threatening), ventricular pauses. * **Other:** Hyperuricemia, elevated creatinine, rash, pruritus. ## Key Drug Interactions * **CYP3A4 Substrates:** Ticagrelor is a moderate CYP3A4 inhibitor. Avoid concomitant use with strong CYP3A4 substrates (e.g., simvastatin, atorvastatin) at high doses; may need to reduce statin dose. * **CYP3A4 Inhibitors:** Potent inhibitors (e.g., ketoconazole, ritonavir) can increase ticagrelor exposure. Avoid concomitant use or consider ticagrelor dose reduction. * **CYP3A4 Inducers:** Inducers (e.g., rifampin, carbamazepine) can decrease ticagrelor exposure. Consider increasing ticagrelor dose or avoiding concomitant use. * **P-glycoprotein Inhibitors:** Potent inhibitors (e.g., cyclosporine) can increase ticagrelor exposure. * **Aspirin:** Increased risk of bleeding, especially in patients treated for ACS. Use in combination as indicated. * **Anticoagulants (e.g., warfarin, direct oral anticoagulants):** Increased risk of bleeding. * **NSAIDs:** Increased risk of bleeding. ## Monitoring * **Bleeding:** Closely monitor for signs and symptoms of bleeding, especially during the initial months of therapy. * **Renal Function:** Monitor creatinine and BUN, particularly in patients with pre-existing renal impairment or those taking other nephrotoxic agents. * **Uric Acid:** Monitor uric acid levels, as hyperuricemia can occur. ## Clinical Pearls * Ticagrelor provides more rapid and consistent P2Y12 inhibition compared to clopidogrel, without the need for metabolic activation. * It is a reversibly binding P2Y12 inhibitor, meaning its effect can be reversed more quickly upon discontinuation compared to clopidogrel (which is irreversibly binding). * Dyspnea is a common side effect and is not typically indicative of underlying cardiac or pulmonary disease. However, if severe or persistent, it warrants investigation. * Consider stopping ticagrelor 5-7 days prior to elective surgery to minimize bleeding risk, depending on patient's bleeding risk and surgical procedure. * If ticagrelor is discontinued prematurely, the risk of stent thrombosis may increase. *** **Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making treatment decisions. Local protocols may dictate specific dosing and management strategies.